Somatostatin receptor type 2 (SSTR2) (SSTR2)

Somatostatin receptor type 2 (SSTR2) is a high-affinity G protein-coupled receptor that mediates the primary inhibitory actions of the hormone somatostatin across various physiological systems (UniProt P30874). It is predominantly expressed in the pituitary gland, pancreas, and gastrointestinal tract, where it regulates the secretion of growth hormone, insulin, glucagon, and various digestive enzymes (PubMed: 21155620). Beyond its endocrine functions, SSTR2 is highly overexpressed in many neuroendocrine tumors (NETs), providing a molecular basis for targeted oncological therapies (StatPearls: Somatostatin). Drugs such as lanreotide act as potent SSTR2 agonists, mimicking the natural hormone to suppress hormonal hypersecretion and exert anti-proliferative effects on tumor cells (FDA: Somatuline Depot). Furthermore, SSTR2 serves as a crucial diagnostic and therapeutic handle in nuclear medicine, enabling the use of radiolabeled somatostatin analogs for tumor imaging and peptide receptor radionuclide therapy (PRRT) (PubMed: 28838981).

Other names

Somatostatin receptor 2SS2RSRIF-1SSTR-2

Agonism of the SSTR2 receptor leads to the inhibition of adenylyl cyclase, reduction of intracellular cAMP levels, and modulation of ion channels, ultimately suppressing hormone release and cell growth (PubMed: 10446900).